Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

les laboratoires servier - indapamidum inn - forðatafla - 1,5 mg

Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

les laboratoires servier* - gliclazidum inn - tafla með breyttan losunarhraða - 30 mg

Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratoires thea s.a.s. - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml + 5 mg/ml

Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratoires thea* - latanoprostum inn; timololum maleat - augndropar, lausn í stakskammtaíláti - 50 míkróg/ml + 5 mg/ml

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

laboratoires delbert - histamín díhýdróklóríð - kyrningahvítblæði, mergbólga, bráð - Ónæmisörvandi, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). verkun ceplene hefur ekki verið sýnt að fullu hjá sjúklingum eldri en 60 ára.

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

laboratoire aguettant - sufentanil salt - verkir - svæfingarlyf - dzuveo is indicated for the management of acute moderate to severe pain in adult patients.

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil stutt og long-term - litlaræxli - Æxlishemjandi lyf - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - brisbólga - Æxlishemjandi lyf - meðferð af sjúklingum krabbamein í brisi í bland með 5 fluorouracil (5 fu) og leukovorin (vuitton), í fullorðinn sjúklingar sem hafa gengið eftir gemcitabin byggt meðferð.

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

les laboratoires servier - pixantrón dimaleat - eitilæxli, non-hodgkin - Æxlishemjandi lyf - pixuvri er ætlað sem einlyfjameðferð til meðferðar hjá fullorðnum sjúklingum með margfalda endurtekna eða eldföstum árásargjarnan hodgkin b-eitilæxli (nhl). ekki hefur verið sýnt fram á ávinning af meðferð með pixantróni hjá sjúklingum þegar þau eru notuð sem fimmta línu eða meiri krabbameinslyfjameðferð hjá sjúklingum sem eru eldföstir við síðasta meðferð.